Alpha 2.0
Login Register
» Journals » Cancer Commun (Lond)

Cancer Communications

Cancer Communications is a peer-reviewed journal dedicated to advancing cancer research and communication. It publishes high-quality articles covering various aspects of cancer biology, diagnosis, treatment, and prevention. With a focus on promoting interdisciplinary collaboration, the journal serves as a platform for scientists, clinicians, and researchers to share their findings and insights, ultimately contributing to the global fight against cancer.
Details
Abbr. Cancer Commun (Lond)
Publisher Wiley
Start 2018
End Continuing
e-ISSN 2523-3548
Country United States
Language English
Specialty Oncology
Metrics
h-index / Ranks: 4440 79
SJR / Ranks: 266 4950
CiteScore / Ranks: 356 19.90
JIF / Ranks: 201 16.2
Recent Articles
1.
Comprehensive DSRCT multi-omics analyses unveil CACNA2D2 as a diagnostic hallmark and super-enhancer-driven EWSR1::WT1 signature gene
Geyer F, Ritter A, Kinn-Gurzo S, Faehling T, Li J, Jarosch A, et al.
Cancer Commun (Lond) . 2025 Mar; PMID: 40088092
No abstract available.
2.
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages
Zhao R, Pan Z, Qiu J, Li B, Qi Y, Gao Z, et al.
Cancer Commun (Lond) . 2025 Mar; PMID: 40084746
Background: Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti-PD-1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti-PD-1 therapy is necessary...
3.
Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond
Huang H, Miao H, Tang J, Li N
Cancer Commun (Lond) . 2025 Mar; PMID: 40077834
No abstract available.
4.
Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients
Petrackova A, Manakova J, Nesnadna R, Kubova Z, Papajik T, Kriegova E
Cancer Commun (Lond) . 2025 Mar; PMID: 40071743
No abstract available.
5.
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma
Mariniello K, Pittaway J, Altieri B, Borges K, Hadjidemetriou I, Ribeiro C, et al.
Cancer Commun (Lond) . 2025 Mar; PMID: 40035383
No abstract available.
6.
Older adults living with gastrointestinal cancers in 2021
Danpanichkul P, Pang Y, Inkongngam T, Namsathimaphorn K, Rakwong K, Kaeosri C, et al.
Cancer Commun (Lond) . 2025 Feb; PMID: 40017390
No abstract available.
7.
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study
Chung C, Shin D, Lee K, Lee S, Han K
Cancer Commun (Lond) . 2025 Feb; PMID: 40017388
No abstract available.
8.
An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial
Wang J, Zhang Q, Sun T, Li H, Cheng Y, Tong Z, et al.
Cancer Commun (Lond) . 2025 Feb; PMID: 40013319
Background: Bireociclib (XZP-3287) is a novel selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT-1 aimed to further...
9.
Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial
He Q, Huang S, Tang D, Cao C, Zhou W, Ling R, et al.
Cancer Commun (Lond) . 2025 Feb; PMID: 39972990
No abstract available.
10.
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm
He B, Hu Y, Wu Y, Wang C, Gao L, Gong C, et al.
Cancer Commun (Lond) . 2025 Feb; PMID: 39960839
Background: Helicobacter pylori (H. pylori) infection contributes significantly to gastric cancer (GC) progression. The intrinsic mechanisms of H. pylori-host interactions and their role in promoting GC progression need further investigation....